JN

Janis Naeve

Partner at Cota Capital

San Francisco, California

Overview 

Janis Naeve is a venture capitalist at Cota Capital in San Francisco, with a focus on investing in biotechnology and drug discovery startups, as well as serving on multiple advisory boards for companies in the life sciences sector. She holds a PhD from the University of Southern California and has made significant investments in companies like NexImmune and Acylin Therapeutics, demonstrating a strong commitment to advancing healthcare innovations through strategic investments and board memberships.

Work Experience 

  • Partner

    2022 - Current

Cota Capital is a technology investment firm that partners with exceptional teams to build and grow timeless companies.

  • Advisory Board Member

    2024

    AI-SDM is newly formed an interdisciplinary research institute funded by NSF to harness the power of AI and social sciences to empower decision-makers with tools that augment human judgment in complex, time-sensitive situations. AI-SDM at CMU collaborates with a diverse network of partners, including academic institutions, government agencies, and non-profit organizations, to develop and deploy impactful solutions that account for risk, trust, and equity in decision-making.

  • Board Observer

    2022

    Excision BioTherapeutics, Inc. is a clinical-stage biotechnology company developing CRISPR-based therapies as potential cures for viral infectious diseases.

  • Board Member

    2022

    Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multiomic analysis for precision medicine, providing advanced tools and analytics for cell and gene therapies.

Mission Bio develops only single-cell multi-omics platform integrating genotype and phenotype for cancer research and biomarker development.

Raised $150,898,729.00 from Novo Holdings, Cota Capital, Soleus Capital, Mayfield Fund, Seabed VC and Agilent Ventures.

  • Board Member

    2022

    Algen, spun out of Jennifer Doudn'as lab is a platform therapeutics and drug discovery company using the world’s leading CRISPR and AI to uncover disease-driving RNA messages to find treatments for cancer, inflammation and other diseases.

Algen Biotechnologies is a therapeutic discovery company that builds a platform to decode functional gene networks.

  • Board Member

    2022

    Probius, spun out of Stanford, is a deep-tech company bridging the data gap between biology and AI by combining physics, mathematics, and biological data into their bioanalytical platform, Quantum Electrochemical Spectroscopy (QES) which translates a sample aliquot into a high-dimensional phenotypic signature, a digital twin, that can be re-analyzed and redefined in the cloud.

Probius specializes in providing services from biomarker discovery to quantification.

  • Board Observer

    2022

    CellFE has developed a scalable, high throughput microfluidic device for the efficient delivery of gene-editing molecules into cells enabling cell and gene therapies.

  • Board Member

    2022 - 2023

    Miroculus applied microfluidics in designing intuitive and flexible platforms based on its patented technology, simplifying complicated Next Generation sequencing protocols. Company was acquired by Integra Biosciences in March 2023

Miroculus is a hands off sample-to-answer solution for molecular testing.

Raised $65,061,364.00 from Endeavor Catalyst, Cota Capital, Section 32, Endeavor Catalyst and Bossa Invest.

  • KidneyX Steering Committee

    2022 - 2022

The Kidney Innovation Accelerator accelerate innovation in kidney disease prevention, diagnosis, and treatment.

  • The Fund@Caltech Advisory Committee

    2020 - 2022

Articles About Janis

Relevant Websites